JRCT ID: jRCT2031200349
Registered date:05/02/2021
A Phase I Study of Runimotamab
Basic Information
Recruitment status | Not Recruiting |
---|---|
Health condition(s) or Problem(s) studied | HER2-expressing cancer (Currently breast cancer and gastric/GEJ cancer only) |
Date of first enrollment | 31/08/2021 |
Target sample size | 537 |
Countries of recruitment | United States,Japan,Australia,Japan,Belgium,Japan,Canada,Japan,Denmark,Japan,France,Japan,Italy,Japan,Korea,Japan,Netherlands,Japan,Singapore,Japan,Spain,Japan,Taiwan,Japan,United Kingdom,Japan |
Study type | Interventional |
Intervention(s) | Runimotamab is administered via IV in escalating doses |
Outcome(s)
Primary Outcome | Safety Occurrence and nature of DLTs Occurrence, nature, and severity of adverse events |
---|---|
Secondary Outcome | Efficacy, Phamacokinetics 1. Serum Concentration 2. AUC 3. Cmax 4. Cmin 5. CL 6. Vss 7. OR 8. DOR 9. ADA |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | <General Inclusion Criteria> -Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 -Life expectancy of at least 12 weeks -Adequate hematologic and end-organ function -Acute, clinically significant treatment-related toxicity from prior therapy must have resolved to Grade </=1 prior to study entry -Left Ventricular Ejection Fraction (LVEF) >/=50% <HER2-Expressing Breast Cancer-Specific Inclusion Criteria> -Locally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BC -Locally advanced or metastatic BC that has relapsed or is refractory to established therapies <HER2-Expressing Gastric/Gastroesophageal (GEJ) Cancer-Specific Inclusion Criteria> -Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy -HER2-expressing tumor (primary tumor or metastasis) as assessed by local lab testing -HER2-positive gastric/GEJ cancer must have received prior trastuzumab, cisplatin (or carboplatin or oxaliplatin or investigational platinum agent) and 5-fluorouracil (5-FU)/capecitabine <HER2-Positive Solid Tumor Specific Inclusion Criteria> -HER2-positive tumor (primary tumor or metastasis) as assessed by local (non-central) laboratory testing -Locally advanced, recurrent, or metastatic incurable malignancy that has progressed after at least one available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care; or for whom a clinical trial of an investigational agent is considered an acceptable treatment option |
Exclude criteria | -Pregnant or breastfeeding, or intending to become pregnant during the study or within 140 days after the last dose of runimotamab -Significant cardiopulmonary dysfunction -Known clinically significant liver disease -Positive for acute or chronic Hepatitis B virus (HBV) infection -Acute or chronic Hepatitis C virus (HCV) infection -Human Immunodeficiency Virus (HIV) seropositivity -Poorly controlled Type 2 diabetes mellitus -History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias -Current treatment with medications that are well known to prolong the Q-wave/T-wave (QT) interval -Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active CNS metastases (progressing or requiring corticosteroids for symptomatic control) -Leptomeningeal disease -Spinal cord compression that has not definitively treated with surgery and/or radiation -History of autoimmune disease -Prior allogeneic stem cell or solid organ transplantation |
Related Information
Primary Sponsor | Iris Chan |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03448042 |
Contact
Public contact | |
Name | Clinical trials information |
Address | 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku Tokyo Tokyo Japan 103-8324 |
Telephone | +81-120189706 |
clinical-trials@chugai-pharm.co.jp | |
Affiliation | Chugai Pharmaceutical Co., Ltd. |
Scientific contact | |
Name | Iris Chan |
Address | 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku Tokyo Tokyo Japan 103-8324 |
Telephone | +81-120-189-706 |
clinical-trials@chugai-pharm.co.jp | |
Affiliation | Genentech, Inc. |